title: From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
abstract: Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group of patients, the median survival time is only 3 years. New treatment approaches are, therefore, required to improve outcome in this disease. Two strategies have emerged with promising results: poly ADP-ribose polymerase enzyme (PARP) inhibitors and targeting angiogenesis. The challenge remains to develop a convenient and accurate method to identify patients likely to benefit from targeted therapy.
authors: César
authors: C
authors: Gómez-Raposo
authors: Marta
authors: M
authors: Mendiola
authors: Jorge
authors: J
authors: Barriuso
authors: David
authors: D
authors: Hardisson
authors: Andrés
authors: A
authors: Redondo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009375:Neoplasms, Glandular and Epithelial / Q000098:blood supply / Q000201:enzymology / Q000235:genetics / Q000628:therapy; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000201:enzymology / Q000235:genetics / Q000628:therapy; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D057285:Precision Medicine / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors